Status:
COMPLETED
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
Lead Sponsor:
Seoul National University Hospital
Conditions:
Cancer
Covid19
Eligibility:
All Genders
20+ years
Brief Summary
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-can...
Eligibility Criteria
Inclusion
- 20 years of age or older
- Patients who are receiving or received anti-cancer drugs
- Those who are not vaccinated against COVID-19 at the time of enrollment
- Written informed consent
Exclusion
- Any contraindications to COVID-19 vaccines
- Those who were already vaccinated
- Those who are on immunosuppressants or infected with HIV
- Those who underwent organ transplantation
- Active infections (for example, pneumonia)
Key Trial Info
Start Date :
March 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT04910295
Start Date
March 26 2021
End Date
December 31 2022
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080